GBA1 and Parkinson disease: However, we had only a small number of non-manifesting carrier fibroblast lines (from individuals aged 60 and 82) and cannot exclude the possibility that there may be subtle differences in glucosylceramidase metabolism and cellular biochemistry between Parkinson’s disease with GBA mutations and non-manifesting carrier cell lines, which would only be apparent in a larger cohort.